文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

立体定向放射外科治疗三叉神经痛:近端与远端等中心靶点疗效比较

Stereotactic Radiosurgery for Trigeminal Neuralgia: A Comparison of Proximal and Distal Isocenter Outcomes.
PubMed 文献 · Adv Radiat Oncol · 2026-09-17

这项多中心回顾性分析纳入2017至2021年接受伽玛刀或直线加速器SRS、处方剂量85 Gy、随访≥1年的三叉神经痛患者86例,比较近端(背根入区)与远端(三叉神经节后区)靶点的疼痛缓解及药物减量。近端靶点完全缓解率更高(46% vs 31%,p=.011),远端靶点任何疼痛改善率更高(90% vs 74%);近端完全停药更常见(39% vs 13%),远端部分减药更常见(75% vs 33%,P=.001)。

要点

  • 近端靶点完全疼痛缓解率46%,高于远端靶点的31%(p=.011)。
  • 远端靶点任何疼痛改善率90%,高于近端靶点的74%。
  • 近端完全停药39% vs 远端13%,远端部分减药75% vs 近端33%(P=.001)。

核心结论

  • 近端与远端靶点SRS治疗三叉神经痛均获得高应答率。
  • 远端靶点可能与更高的任何疼痛改善率相关。
  • 近端靶点可能与更高的完全疼痛缓解率和完全停药率相关。
  • 上述发现为假设生成性,需进一步研究两种靶点的疗效与安全性差异。

研究设计与样本

  • 多中心回顾性分析,纳入2017至2021年接受伽玛刀或直线加速器SRS治疗的三叉神经痛患者。
  • 随访至少1年,所有患者处方剂量为85 Gy至等中心。
  • 靶点分为近端(背根入区)和远端(三叉神经节后区)。
  • 共纳入86例:近端靶点54例(63%),远端靶点32例(37%)。
  • 采用log-rank检验和Cox比例风险分析比较结局。

主要发现

  • 近端靶点组中位年龄63岁、女性72%;远端靶点组中位年龄66岁、女性71%。
  • 总体疼痛缓解率:近端74%,远端90%。
  • 完全疼痛缓解率:近端46%,远端31%(p=.011)。
  • 疼痛缓解持续时间两组无显著差异(p=.18)。
  • 完全停药:近端39% vs 远端13%;部分减药:远端75% vs 近端33%(P=.001)。

关键数值与推荐

  • 所有患者SRS处方剂量为85 Gy至等中心。
  • 疼痛缓解由患者报告,分为完全、部分或无缓解。
  • 近端靶点定义为背根入区,远端靶点定义为三叉神经节后区。

临床怎么用

  • 对于药物难治性三叉神经痛,近端和远端靶点SRS均可作为非侵入性选择。
  • 若治疗目标侧重完全疼痛缓解或完全停药,可考虑近端靶点。
  • 若治疗目标侧重获得任何疼痛改善,可考虑远端靶点。
  • 靶点选择需结合患者个体情况,并认识到当前证据为假设生成性。

局限性

  • 回顾性研究设计。
  • 样本量较小(共86例)。
  • 作者指出结果为假设生成性,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Trigeminal neuralgia (TN) is a chronic neuropathic pain condition affecting the trigeminal nerve, with an incidence of approximately 4 to 5 per 100,000 persons annually, increasing to 20 per 100,000 after age 60 years, and a female-to-male ratio of approximately 3:2. Stereotactic radiosurgery (SRS) delivered by Gamma Knife or linear accelerators is a noninvasive alternative to surgical approaches for medically refractory cases. Although SRS for TN is commonly performed, consensus regarding optimal anatomic targeting remains lacking, with the 2 most common targets being the dorsal root entry zone (proximal) and the retrogasserian zone (distal). This study aimed to evaluate treatment outcomes in patients with TN treated with SRS based on proximal versus distal isocenter target locations. METHODS AND MATERIALS: This multicenter retrospective analysis included patients treated for TN between 2017 and 2021 with Gamma Knife or linear accelerator-based SRS who were followed for at least 1 year. All patients received 85 Gy prescribed to the isocenter, located in either the dorsal root entry zone (proximal) or the retrogasserian zone (distal). Patient-reported pain relief was recorded as complete, partial, or absent. Duration of pain relief and medication de-escalation were also assessed. Outcomes were compared using the log-rank test and Cox proportional hazards analysis. RESULTS: Eighty-six patients were included: 54 of 86 (63%) treated with proximal targeting (median age, 63 years; 72% women) and 32 of 86 (37%) with distal targeting (median age, 66 years; 71% women). Overall pain relief rates were 74% (proximal) and 90% (distal), although complete pain relief rates were 46% (proximal) and 31% (distal) (p = .011). Duration of pain relief did not differ significantly between groups (p = .18). Complete medication de-escalation was more frequent with proximal targeting (39% vs 13%), although partial de-escalation was more common with distal targeting (75% vs 33%) (P = .001). CONCLUSIONS: Both proximal and distal targeting approaches achieve high response rates for TN. Distal targeting may be associated with higher rates of any pain improvement, whereas proximal targeting may be associated with higher rates of complete pain relief and complete medication discontinuation. These findings are hypothesis-generating and warrant further investigation of efficacy and safety differences between these 2 approaches.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hopkins, Qian, Boulis, et al. Stereotactic Radiosurgery for Trigeminal Neuralgia: A Comparison of Proximal and Distal Isocenter Outcomes. Adv Radiat Oncol. 2026. PMID: 42959311. doi:10.1016/j.adro.2026.102220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。